SUMO1P3 and urinary bladder carcinoma: To validate the potential use of SUMO1P3 as a biomarker for the progression of bladder cancer from superficial to more aggressive phenotypes, we defined a validation cohort composed of 65 new patients, the characteristics of which are summarized in Table 2.